Document is current

Article History

Received: 3 July 2018

Accepted: 12 September 2018

First Online: 1 October 2018

Ethics approval and consent to participate

: Local ethics committee approval of the study was obtained from the CPP – Ile-de-France.

: Not applicable.

: YN received speech honoraria from Actelion and Orphan Europe; and received travel funding from Actelion, Shire and Genzyme. PL has received presentation honoraria from Actelion Pharmaceuticals France. CG received from Actelion honorarium for participation in an advisory board and funding for inscriptions and travels for congresses. MA declares honoraria from Actelion, Abbvie and Teva. ER received research support from Merz-Pharma, Orkyn, Aguettant, IP Santé, Ultragenix, and UCB pharma; served on scientific advisory boards for Orkyn, Ultragenix, Retrophin and Merz-Pharma; received speech honoraria from Orkyn, Aguettant, Merz-Pharma and Ultragenix; and received travel funding from the Elivie, the Dystonia Coalition, the Dystonia Medical Research Foundation, the Movement Disorders Society, the European Academy of Neurology. MTV has received honoraria and travel reimbursement from Actelion Pharmaceuticals Ltd., Sucampo Pharmaceuticals Inc. and Mallinckrodt Pharmaceuticals as a member of advisory committees and/or guest speaker, travel reimbursement from Vtesse, and honoraria from Shire as a member of a data and safety monitoring board. BH has received travel expenses from, and attended meetings funded and organized by Actelion Pharmaceuticals Ltd., Biomarin, Genzyme Corporation and Shire HGT, and has received presentation honoraria from Actelion Pharmaceuticals Ltd. ALHM, XA, CT, PC, AD, CL, LM, CT, BA, VD, TDdG, and FL have no conflicts of interest to declare.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.